Clinical trials: Angiography, Digital Subtraction
Peripheral Arterial Occlusive Disease
Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA
The purpose of this study is to compare ISOVUE-250 and VISIPAQUE 270 for motion artifact and pain following intraarterial injection for peripheral DSA.
- Trial name
- NCT00740207
- Testing
- VISIPAQUE 270, Isovue 250
- Volunteers
- 33 people
- Sponsor
- Bracco Diagnostics, Inc
Cardiovascular Disease
X-ray Dose Reduction Study for Endovascular Interventional Radiology
ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly.
- Trial name
- NCT01599741
- Testing
- Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology., Normal dose DSA with conventional X-ray imaging technology
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Peripheral Arterial Occlusive Disease
Isovue in Peripheral Digital Subtraction Angiography (DSA)
No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.
- Trial name
- NCT01075217
- Testing
- iopamidol, iodixanol
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Bracco Diagnostics, Inc
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
- Trial name
- CONSCIOUS-1 (NCT00111085)
- Testing
- Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h
- Where
- 16 sites in United States, Canada
- Volunteers
- 413 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Peripheral Vascular Diseases
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
The particular aim of this study is the comparison of the diagnostic results of MRA images upon application of Vasovist (gadofosveset), a contrast agent not yet available on the market, with the MRA images upon application of a…
- Trial name
- NCT00296855
- Testing
- Vasovist (BAY86-5283, MS-325)
- Where
- 26 sites in Argentina, Austria and 4 more
- Volunteers
- 261 people
- Sponsor
- Bayer